Cota reels in $40M in series C funding to advance its analytics program

20 dollar bills
Cota reeled in $40 million in series C funding to advance its analytics program. (StockSnap)

Cota, a healthcare data analytics company, raised $40 million in series C financing. The company said the funds will be used to advance its Cota Nodal Address (CNA) disease classification system.

The round of funding was led by IQVIA. EW Healthcare Partners was also a major participant. Joining in the funding round were Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings.

The company said the money will be used to scale its product across providers, payers and life science companies. The company describes its CNA product as a “precision disease classification system” developed using comprehensive real-world data.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

"With our CNA classification system and powerful analytics, we are confident that Cota will revolutionize both patient care and healthcare economics,” John Hervey, Cota’s chief executive, said in a statement. “The depth and richness of our real-world evidence set empowers life sciences companies to gain new insights into their compounds, accelerate market applications and support clinical trials.”

As the lead in the round, IQVIA received a seat on Cota's board of directors.

Read more on

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

Five years after Congress passed a law to reduce unnecessary MRIs and CT scans, federal officials have yet to implement it.